Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma

Blood

Volumn 103, Issue 5, 2004, Pages 1755-1762

  Marshall, Neil A ^b   Christie, Linsey E ^b   Munro, Laura R ^b   Culligan, Dominic J ^b   Johnston, Peter W ^b   Barker, Robert N ^b   Vickers, Mark A ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CD4 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR; MITOGENIC AGENT; T LYMPHOCYTE ANTIBODY;

ADOLESCENT; ADULT; ARTICLE; CELL CONTACT; CLINICAL ARTICLE; CLONAL ANERGY; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HODGKIN DISEASE; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; LYMPH NODE; LYMPHOCYTIC INFILTRATION; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REED STERNBERG CELL; T LYMPHOCYTE; TH2 CELL; TUMOR IMMUNITY;

EID: 1442283424     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-07-2594     Document Type: Article

References (43)

1. Skinnider BF, Mak TW. The role of cytokines in classical Hodgkin lymphoma. Blood. 2002;99:4283-4297.
2. Reed DM. On pathological changes in Hodgkin's disease, with especial reference to its relation to tuberculosis. Johns Hopkins Hosp Rep. 1902;10:133-196.
3. Green I, Corse PF. A study of skin homografting in patients with lymphomas. Blood. 1959;14:235-245.
4. Miller DG, Lizardo JG, Snyderman RK. Homologous and heterologous skin tranplantation in patients with lymphomatous disease. J Natl Cancer Inst. 1961;26:569-579.
5. Baglin TP, Joysey VC, Horsford J, Johnson RT, Broadbent V, Marcus RE. Transfusion-associated graft-versus-host disease in patients with Hodgkin's disease and T cell lymphoma. Transfus Med. 1992;2:195-199.
6. Levy R, Kaplan HS. Impaired lymphocyte function in untreated Hodgkin's disease. N Engl J Med. 1974;290:181-186.
7. Hellinger SM, Herzig GP. Impaired cell-mediated immunity in Hodgkin's disease mediated by suppressor lymphocytes and monocytes. J Clin Invest. 1978;61:1620-1627.
8. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clone, I: definition according to profiles of lymphokine activities and secreted proteins. J Immunol. 1986;136:2348-2357.
9. Roncarolo M, Levings MK. The role of different subsets of T regulatory cells in controlling autoimmunity. Curr Opin Immunol. 2000;12:676-683.
10. Shevach EM. Regulatory T cells in autoimmunity. Annu Rev Immunol. 2000;18:423-449.
11. Shevach EM. Wood KJ, Sakaguchi S. Regulatory T cells in transplantation tolerance. Nat Rev Immunol. 2003;3:199-210.
12. Levings MK, Roncarolo MG. T-regulatory 1 cells: a novel subset of CD4 T cells with immunoregulatory properties. J Allergy Clin Immunol. 2000;106:S109-S112.
13. Weiner HL. Induction and mechanism of action of transforming growth factor-beta-secreting Th3 regulatory cells. Immunol Rev. 2001;182:207-214.
14. Piccirillo CA, Letterio JJ, Thornton AM, et al. CD4(+)CD25(+) regulatory T cells can mediate suppressor function in the absence of transforming growth factor betal production and responsiveness. J Exp Med. 2002;196:237-246.
15. McHugh RS, Shevach EM. The role of suppressor T cells in regulation of immune responses. J Allergy Clin Immunol. 2002;110:693-702.
16. Poppema S, van den Berg A. Interaction between host T cells and Reed-Stemberg cells in Hodgkin lymphomas. Semin Cancer Biol. 2000;10:345-350.
17. Dukers DF, Jaspars LH, Vos W, et al. Quantitative immunohistochemical analysis of cytokine profiles in Epstein-Barr virus-positive and -negative cases of Hodgkin's disease. J Pathol. 2000;190:143-149.
18. Herbst H, Foss H-D, Samoi J, et al. Frequent expression of intedeukin-10 by Epstein-Barr virus-harboring tumor cells of Hodgkin's disease. Blood. 1996;87:2918-2929.
19. Skinnider BF, Ella AJ, Gascoyne RD, et al. Interleukin 13 and intedeukin 13 receptor are frequently expressed by Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood. 2001;97:250-255.
20. Alexander FE, Jarrett RF, Lawrence D, et al. Risk factors for Hodgkin's disease by Epstein-Barr virus (EBV) status: prior infection by EBV and other agents. Br J Cancer. 2000;82:1117-1121.
21. Weiss LM, Strickler JG, Warnke RA, Purtilo DT, Sklar J. Epstein-Barr viral DNA in tissues of Hodgkin's disease. Am J Pathol. 1987;129:86-91.
22. Pallesen G, Hamilton-Dutoit SJ, Rowe M, Young LS. Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease. Lancet. 1991;337:320-322.
23. Frisan T, Sjoberg J, Dolcetti R, et al. Local suppression of Epstein-Barr virus (EBV)-specific cytotoxicity in biopsies of EBV-positive Hodgkin's disease. Blood. 1995;86:1493-1501.
24. Chapman ALN, Rickinson AB, Thomas WA, Jarrett RF, Crocker J, Lee SP. Epstein-Barr virus-specific cytotoxic T lymphocyte responses in the blood and tumour site of Hodgkin's disease patients: implications for a T-cell-based therapy. Cancer Res. 2001;61:6219-6226.
25. Marshall NA, Vickers MA, Barker RN. Regulatory T cells secreting IL-10 dominate the immune response to EBV latent membrane protein 1. J Immunol. 2003;170:6183-6189.
26. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med. 1998;339:1506-1514.
27. Plebanski M, Saunders M, Burtles SS, Crowe S, Hooper DC. Primary and secondary human in vitro T-cell responses to soluble antigens are mediated by subsets bearing different CD45 isoforms. Immunology. 1992;75:86-91.
28. Devereux G, Hall AM, Barker RN. Measurement of T-helper cytokines secreted by cord blood mononuclear cells in response to allergens. J Immnunol Methods. 2000;234:13-22.
29. Hall AM, Ward FJ, Vickers MA, Stott LM, Urbaniak SJ, Barker RN. Interleukin-10-mediated regulatory T-cell responses to epitopes on a human red blood cell autoantigen. Blood. 2002;100:4529-4536.
30. Kim WU, Cho ML, Kim SI, et al. Divergent effect of cyclosporine on Th1/Th2 type cytokines in patients with severe, refractory rheumatoid arthritis. J Rheumatol. 2000;27:324-331.
31. Read S, Malmstrom V, Powrie F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med. 2000;192:295-302.
32. Ohshima K, Akaiwa M, Umeshita R, Suzumiya J, Izuhara K, Kikuchi M. Interleukin-13 and interleukin-13 receptor in Hodgkin's disease: possible autocrine mechanism and involvement in fibrosis. Histopathology. 2001;38:368-375.
33. Tesch H, Gunther A, Abts H, et al. Expression of interleukin-2R alpha and interleukin-2R beta in Hodgkin's disease. Am J Pathol. 1993;142:1714-1720.
34. Vandenborre K, Delabie J, Boogaerts MA, et al. Human CTLA-4 is expressed in situ on T lymphocytes in germinal centers, in cutaneous graft-versus-host disease and in Hodgkin's disease. Am J Pathol. 1998;152:963-973.
35. Roncarolo MG, Bacchetta R, Bordignon C, Narula S, Levings MK. Type 1 T regulatory cells. Immunol Rev. 2001;182:68-79.
36. Hsu SM, Lin J, Xie SS, Hsu PL, Rich S. Abundant expression of transforming growth factor-beta 1 and -beta 2 by Hodgkin's Reed-Sternberg cells and by reactive T lymphocytes in Hodgkin's disease. Hum Pathol. 1993;24:249-255.
37. Golgher D, Jones E, Powrie F, Elliott T, Gallimore A. Depletion of CD25+ regulatory cells uncovers immune responses to shared murine tumor rejection antigens. Eur J Immunol. 2002;32:3267-3275.
38. Egen JG, Kuhns MS, Allison JP. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol. 2002;3:611-618.
39. Liyanage UK, Moore TT, Joo HG, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreatic or breast adenocarcinoma. J Immunol. 2002;169:2756-2761.
40. Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein B. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res. 2003;9:606-612.
41. Gottschalk S, Edwards OL, Huls MH, et al. Generating CTL against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies. Blood. 2003;101:1905-1912.
42. Culo F, Klapan I, Kolak T. The influence of cyclophosphamide on antitumor immunity in mice bearing late-stage tumors. Cancer Immunol Immunother. 1993;36:115-122.
43. Andrade-Mena CE. Cyclophosphamide-induced tumour regression of cyclophosphamide-resistant L5178Y lymphoma through suppressor cells elimination. Int J Tissue React. 1994;16:95-103.